High temporal resolution proteome and phosphoproteome profiling of stem cell-derived hepatocyte development.
2D versus 3D differentiation
CP: Cell biology
CP: Stem cell research
hepatocyte differentiation
post-translational modifications
proteomics
stem cell-derived organoids
Journal
Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691
Informations de publication
Date de publication:
29 03 2022
29 03 2022
Historique:
received:
24
07
2021
revised:
29
10
2021
accepted:
09
03
2022
entrez:
30
3
2022
pubmed:
31
3
2022
medline:
2
4
2022
Statut:
ppublish
Résumé
Primary human hepatocytes are widely used to evaluate liver toxicity of drugs, but they are scarce and demanding to culture. Stem cell-derived hepatocytes are increasingly discussed as alternatives. To obtain a better appreciation of the molecular processes during the differentiation of induced pluripotent stem cells into hepatocytes, we employ a quantitative proteomic approach to follow the expression of 9,000 proteins, 12,000 phosphorylation sites, and 800 acetylation sites over time. The analysis reveals stage-specific markers, a major molecular switch between hepatic endoderm versus immature hepatocyte-like cells impacting, e.g., metabolism, the cell cycle, kinase activity, and the expression of drug transporters. Comparing the proteomes of two- (2D) and three-dimensional (3D)-derived hepatocytes with fetal and adult liver indicates a fetal-like status of the in vitro models and lower expression of important ADME/Tox proteins. The collective data enable constructing a molecular roadmap of hepatocyte development that serves as a valuable resource for future research.
Identifiants
pubmed: 35354033
pii: S2211-1247(22)00352-7
doi: 10.1016/j.celrep.2022.110604
pii:
doi:
Substances chimiques
Proteome
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
110604Subventions
Organisme : Medical Research Council
ID : MR/R006237/1
Pays : United Kingdom
Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests B.K. and M.W. are founders and shareholders of OmicScouts and MSAID. They have no operational role in either company.